The Nobel Assembly announced Monday that the 2026 Nobel Prize in Physiology or Medicine goes to three researchers whose work created a powerful new tool for studying the brain. Karl Deisseroth, a Howard Hughes Medical Institute investigator and Stanford University professor, Peter Hegemann of Humboldt University in Berlin, and Georg Nagel, formerly of the University of Würzburg, were recognized for their development of optogenetics.
What is optogenetics?
Optogenetics combines genetics and optics to give specific brain cells the ability to respond to light. The technique began when Hegemann and Nagel studied a single‑celled green algae that swims toward light. They identified a protein that opens an ion channel when illuminated with blue light, creating an electrical impulse. By inserting the gene for this protein into other cells, those cells become light‑sensitive.
Deisseroth then adapted the gene to create a light‑controlled switch for neurons in living mice. He also engineered tiny fiber‑optic cables that deliver precise pulses of light to the modified cells, allowing researchers to turn individual neurons on or off within milliseconds – the same speed at which brain cells naturally communicate.
Why the discovery matters
According to Patrick Forcelli, chair of the pharmacology and physiology department at Georgetown University, optogenetics gives scientists a way to manipulate brain circuits with unprecedented precision. “It has let us go from a ‘Rand McNally’ road atlas of the brain to something more akin to ‘Google Earth,’” he said.
The method is already reshaping neuroscience labs worldwide. Researchers use it to map functional wiring diagrams, explore how specific circuits drive behavior, and investigate the neural basis of diseases such as blindness, depression, addiction and dementia. The technique also underpins emerging therapeutic approaches, including experimental treatments for autism, schizophrenia and a genetic form of vision loss called retinitis pigmentosa.
Impact on future therapies
While optogenetics remains primarily a research tool, its ability to control neurons in real time offers a blueprint for future medical interventions. Scientists are exploring ways to translate the light‑controlled switches into clinical therapies that could restore lost functions or correct abnormal brain activity.
Abdel El Manira, a member of the Nobel Assembly, emphasized that the technology’s reach extends beyond basic science. “It has also helped reveal how specific brain circuits are disrupted, with implications for conditions such as blindness, depression, addiction and dementia,” he noted.
Personal note from a laureate
Deisseroth, who describes himself as a night owl, said he learned of the award while preparing to make sandwiches for his children. “No real sleep was achieved,” he told the Associated Press, adding that his next priority was to ensure his kids had school lunches before returning to his research.
The Nobel Prize ceremony will take place at the Karolinska Institute in Stockholm, kicking off Nobel Week. This year’s award includes a prize purse of 12 million Swedish kronor (about $1.2 million), which may be shared among the laureates.
Original reporting: Oklahoma City News Feed (HLL/CB) — read the source article.
